Samsung Biologics (KRX: 207940.KS), a world-leading contract development and manufacturing organization (CDMO), has reported record-breaking financial results for the fourth quarter and full fiscal year [Read More…]
Abbott concludes 2025 with double-digit earnings growth and a powerful surge in Medical Device sales. With a new 2026 organic growth forecast of 6.5%–7.5% and a major entry into cancer diagnostics via the Exact Sciences acquisition, the healthcare leader signals a year of accelerated expansion ahead.
ohnson & Johnson has concluded a ‘catapult year’ with $94.2 billion in revenue, driven by a surge in oncology sales and strategic MedTech innovations. As the healthcare giant prepares to spin off its orthopaedics business, it sets its sights on becoming the first healthcare company to surpass the $100 billion annual revenue milestone in 2026.
In a major shift for the pharmaceutical industry, AbbVie (NYSE: ABBV) announced on Monday a sweeping, voluntary agreement with the Trump administration designed to lower [Read More…]
In a move that signals a significant shift in the relationship between Big Pharma and the federal government, Johnson & Johnson (NYSE: JNJ) announced a [Read More…]
Eli Lilly expands its clinical-stage portfolio with the $1.2 billion acquisition of Ventyx Biosciences, securing high-potential oral NLRP3 inhibitors to treat chronic inflammation and neurodegenerative disorders.
In its first major move of 2026, Amgen (NASDAQ: AMGN) has announced the acquisition of Dark Blue Therapeutics Ltd., a privately held U.K. biotech specializing [Read More…]
Novo Nordisk has officially launched the Wegovy® pill, the first-ever oral GLP-1 medication for weight management in adults. Following FDA approval in late 2025, this once-daily pill offers a needle-free alternative to injections, demonstrating an average weight loss of up to 17% in clinical trials. With tiered pricing starting at $149 per month for self-pay patients, oral Wegovy is now available through major U.S. pharmacies and select telehealth platforms.
Johnson & Johnson has finalized a landmark $3.05 billion acquisition of Halda Therapeutics, integrating the clinical-stage biotech’s proprietary RIPTACâ„¢ platform. This strategic move adds HLD-0915—a next-generation oral therapy for prostate cancer to J&J’s portfolio, signaling a major shift toward precision, “cell-killing” mechanisms designed to overcome traditional treatment resistance.
In a major move to improve affordability and counter the compounded drug market, Eli Lilly has cut the monthly cost of Zepbound to $299 for the starter dose. Available exclusively through LillyDirect, these new single-dose vials offer a significant discount for patients without insurance coverage. Read the full details on the new pricing structure and how it impacts the weight-loss drug market.
